Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review
-
Published:2023-11-30
Issue:6
Volume:13
Page:1549-1560
-
ISSN:2039-7283
-
Container-title:Clinics and Practice
-
language:en
-
Short-container-title:Clinics and Practice
Author:
Luciano Angelo12, Liguori Luigi12ORCID, Polcaro Giovanna1ORCID, Sabbatino Francesco1ORCID, Pepe Stefano1
Affiliation:
1. Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy 2. Oncology Unit, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, 80131 Naples, Italy
Abstract
Non-small cell lung cancer (NSCLC) is the second most common cancer worldwide, resulting in 1.8 million deaths per year. Most patients are diagnosed with a metastatic disease. Brain metastases are one of the most common metastatic sites and are associated with severe neurological symptoms, shorter survival, and the worst clinical outcomes. Brain radiotherapy and systemic oncological therapies are currently used for controlling both cancer progression and neurological symptoms. Brain radiotherapy includes stereotactic brain ablative radiotherapy (SBRT) or whole brain radiotherapy (WBRT). SBRT is applied for single or multiple (up to ten) small (diameter less than 4 cm) lesions, whereas WBRT is usually applied for multiple (more than ten) and large (diameter greater than 4 cm) brain metastases. In both cases, radiotherapy application may be viewed as an overtreatment which causes severe toxicities without achieving a significant clinical benefit. Thus far, a number of scoring systems to define the potential clinical benefits derived from brain radiotherapy have been proposed. However, most are not well established in clinical practice. In this article, we present a clinical case of a patient with advanced NSCLC carrying a BRAFV600E mutation and brain metastases. We review the variables in addition to applicable scoring systems considered to have potential for predicting clinical outcomes and benefits of brain radiotherapy in patients with advanced NSCLC and brain metastases. Lastly, we highlight the unmet need of specific scoring systems for advanced NSCLC patients with brain metastases carrying oncogene alterations including BRAFV600E mutations.
Reference27 articles.
1. Cancer Statistics, 2023;Siegel;CA Cancer J. Clin.,2023 2. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment;Duma;Mayo Clin. Proc.,2019 3. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship;Molina;Mayo Clin. Proc.,2008 4. Ferrara, M.G., Di Noia, V., D’Argento, E., Vita, E., Damiano, P., Cannella, A., Ribelli, M., Pilotto, S., Milella, M., and Tortora, G. (2020). Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers, 12. 5. Immunotherapy in Non-Small Cell Lung Cancer: Past, Present, and Future Directions;Punekar;Front. Oncol.,2022
|
|